{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Overall response with elotuzumab and lenalidomide for each study arm. Overall Response is defined as best Overall Response, as Complete Response or Partial Response. Response will be assessed per the uniform response criteria of the International Myeloma Working Group(IMWG). Myeloma participants enrolled in this clinical study will be assessed for disease response after every cycle. Complete Response= Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates; Partial Response= ≥50% reduction of serum M-protein plus reduction in 24 h urinary M-protein by ≥90% or to \\<200 mg per 24 h;","groups":[{"description":"Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.\n\nLenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule.\n\nElotuzumab: Elotuzumab according to dosing schedule outlined in treatment arms.\n\nLenalidomide: Lenalidomide according to dosing schedule outlined in treatment arms.\n\nDexamethasone: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.\n\nDuring the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert.","id":"OG000","title":"A: Elotuzumab + Lenalidomide at 25 mg"},{"description":"Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.\n\nLenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule.\n\nElotuzumab: Elotuzumab according to dosing schedule outlined in treatment arms.\n\nLenalidomide: Lenalidomide according to dosing schedule outlined in treatment arms.\n\nDexamethasone: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.\n\nDuring the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert.","id":"OG001","title":"B: Elotuzumab + Lenalidomide at 10 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 60 days post last study treatment","title":"Overall Response","type":"SECONDARY","unitOfMeasure":"Participants"}